Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: This study compared the outcomes between intensive and nonintensive insulin regimens and assessed the predictive factors for failing to achieve the glycated hemoglobin (A1C) goals in type-2-diabetes-mellitus (T2DM) patients requiring insulin therapy.
Methods: A single-center, retrospective assessment of the medical records of 125 T2DM patients undergoing intensive (46 patients) and nonintensive insulin therapy (79 patients) were conducted.
Results: No significant differences were found when the intensive and nonintensive insulin therapy groups were compared in terms of the percentage decreases of glucose and A1C levels. The mean A1C levels of the nonintensive and intensive groups declined from 11.15% and 11.30% to 7.97% and 8.06%, respectively.
Conclusions: Both intensive and nonintensive insulin therapies improved the baseline glycemic parameters but being overweight or obese and/or being reluctant to dietary recommendations led to treatment failures regardless of the insulin regimen.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.23736/S2724-6507.20.03323-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The association between inflammation and glucose levels in hospitalised patients with type 2 diabetes.
Diabetes Obes Metab
October 2025
Department of Endocrinology and Nephrology, Copenhagen University Hospital, Hilleroed, Denmark.
Aims: Stress-induced hyperglycaemia can exacerbate existing diabetes. However, the relationship between inpatient inflammation and glucose levels is not well understood.
Materials And Methods: This post hoc analysis utilised data from the DIATEC trial (N = 166), a two-arm randomised controlled trial comparing glucose management with real-time continuous glucose monitoring (CGM) or point-of-care glucose testing in non-intensive care unit (non-ICU) patients with type 2 diabetes treated with a basal-bolus insulin regimen.
Short-term CGM as a tool to optimize glycemic control and defer intensive insulin therapy in people with poorly controlled type 2 diabetes: a Belgian real-life study.
Acta Clin Belg
August 2025
Division of Endocrinology and Nutrition, Cliniques universitaires St-Luc and Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.
Objective: Continuous glucose monitoring (CGM) benefits type 2 diabetes (T2D) patients on multiple daily insulin injections (MDI), but its role in non-intensive insulin therapy remains underexplored. This study evaluates whether a short-term CGM non-blinded can postpone the escalation to multiple daily insulin injections in people with poorly controlled T2D.
Methods: This retrospective real-world study analyzed data from 309 adults with T2D in primary care who used a 10 or 14-day CGM (2020-2024).
Real-world glucose-lowering strategies for managing glucocorticoid-induced diabetes in non-intensive hospital settings.
Eur J Intern Med
June 2025
Diabetes Unit, Niguarda Ca` Granda Hospital, Piazza Ospedale Maggiore 3, 20162 Milan, MI, Italy. Electronic address:
Continuous glucose monitoring during intravenous insulin infusion treatment: Assessing accuracy to enable future clinical utility.
Diabet Med
September 2025
Department of Diabetes & Endocrinology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
Aims: Continuous glucose monitoring (CGM) during intravenous insulin infusions (IVII) could reduce blood glucose (BG) testing burden in hospital, however CGM accuracy concerns exist. We aimed to assess CGM accuracy during IVII.
Methods: This multi-centre observational study included adults with type 1 diabetes (T1D) who required IVII treatment during hospital admission whilst wearing their own CGM devices (Abbott FreeStyle Libre 2, Medtronic Guardian 3, Dexcom G6).
Introduction: Effective management of type 2 diabetes mellitus (T2DM) consists of lifestyle modification and therapy optimisation. While glycaemic monitoring can be used as a tool to guide these changes, this can be challenging with self-monitoring of blood glucose (SMBG). The FreeStyle Libre 3 (FSL3) is a real-time continuous glucose monitoring (CGM) system designed to replace SMBG.
View Article and Find Full Text PDF